{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:48:03Z","timestamp":1787042883081,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515011600"],"award-info":[{"award-number":["2023A1515011600"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","award":["A2022121"],"award-info":[{"award-number":["A2022121"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ijrobp.2023.09.031","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T23:08:46Z","timestamp":1699312126000},"page":"770-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase 2 Clinical Trial of Simultaneous Boost Intensity Modulated Radiation Therapy With 3 Dose Gradients in Patients With Stage I-II Nasal Type Natural Killer\/T-Cell Lymphoma: Long-Term Outcomes of Survival and Quality of Life"],"prefix":"10.1016","volume":"118","author":[{"given":"Shaoqing","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.09.031_bib0001","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2021.02.011","article-title":"Modern radiation therapy for extranodal nasal-type NK\/T-cell lymphoma: Risk-adapted therapy, target volume, and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"110","author":"Qi","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0002","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0003","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1470-2045(19)30799-5","article-title":"Genetic risk of extranodal natural killer T-cell lymphoma: A genome-wide association study in multiple populations","volume":"21","author":"Lin","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0004","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijrobp.2018.05.046","article-title":"Phase 2 study of first-line intensity modulated radiation therapy followed by gemcitabine, dexamethasone, and cisplatin for high-risk, early stage extranodal nasal-type NK\/T-cell lymphoma: The GREEN study","volume":"102","author":"Qi","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0006","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: Analysis from a multicenter study","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0007","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","article-title":"Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma","volume":"24","author":"Li","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0008","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdh143","article-title":"Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)\/T-cell lymphoma: A single institute survey in Taiwan","volume":"15","author":"You","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0009","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijrobp.2007.05.073","article-title":"Early or up-front radiotherapy improved survival of localized extranodal NK\/T-cell lymphoma, nasal-type in the upper aerodigestive tract","volume":"70","author":"Huang","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0010","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2013.08.040","article-title":"High-dose and extended-field intensity modulated radiation therapy for early-stage NK\/T-cell lymphoma of Waldeyer's ring: Dosimetric analysis and clinical outcome","volume":"87","author":"Bi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0011","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ijrobp.2011.02.039","article-title":"Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK\/T-cell lymphoma","volume":"82","author":"Wang","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0012","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.ijrobp.2010.10.040","article-title":"Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK\/T-cell lymphoma","volume":"82","author":"Li","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0013","first-page":"377","article-title":"Preliminary results of a phase II prospective clinical study of early-stage nasal NK\/T-cell lymphoma with extended involved-field intensity-modulated radiotherapy","volume":"24","author":"Niu","year":"2015","journal-title":"Chin J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2019.06.359","article-title":"Simultaneous integrated boost IMRT with three dose gradients in patients with stage I-II nasal cavity and Waldeyer's ring natural killer\/T-cell lymphoma: A prospective phase II clinical trial","volume":"105","author":"Niu","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0015","doi-asserted-by":"crossref","first-page":"11480","DOI":"10.18632\/oncotarget.14006","article-title":"Radiotherapy improves survival in early stage extranodal natural killer\/T cell lymphoma patients receiving asparaginase-based chemotherapy","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0016","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/hon.2970","article-title":"Promising clinical efficacy and acceptable safety profile of sequential P-GEMOX and radiotherapy for localized ENKTL","volume":"40","author":"Yoon","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2018.05.001","article-title":"Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus","volume":"128","author":"Lambrecht","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0018","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0019","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/S0959-8049(00)00186-6","article-title":"A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group","volume":"36","author":"Bjordal","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0020","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1080\/10428194.2019.1602265","article-title":"Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: A multicenter study from the China Lymphoma Collaborative Group (CLCG)","volume":"60","author":"Qi","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0021","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00277-015-2390-3","article-title":"The extent of local tumor invasion predicts prognosis in stage IE nasal natural killer\/T-cell lymphoma: A novel T staging system for risk stratification","volume":"94","author":"Bi","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0022","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1182\/blood-2005-05-2056","article-title":"Local tumor invasiveness is more predictive of survival than international prognostic index in stage I(E)\/II(E) extranodal NK\/T-cell lymphoma, nasal type","volume":"106","author":"Kim","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0023","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2147\/OTT.S158126","article-title":"Patterns of local failures and suggestions for reduction of clinical target volume for nasopharyngeal carcinoma patients without cervical lymph node metastasis","volume":"11","author":"Li","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0024","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: A multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0025","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3349\/ymj.2016.57.4.846","article-title":"The roles of radiotherapy and chemotherapy in the era of multimodal treatment for early-stage nasal-type extranodal natural killer\/T-cell lymphoma","volume":"57","author":"Kim","year":"2016","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0026","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s00277-021-04700-y","article-title":"The optimal timing of radiotherapy in the combination treatment of limited-stage extranodal natural killer\/T-cell lymphoma, nasal type: An updated meta-analysis","volume":"100","author":"Cui","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2018.04.026","article-title":"Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK\/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)","volume":"129","author":"Deng","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0028","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clml.2019.10.010","article-title":"Prognostic nomogram for overall survival in early stage extranodal natural killer\/T cell lymphoma treated with high-dose radiotherapy","volume":"20","author":"Huang","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0029","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1002\/cncr.30697","article-title":"The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States","volume":"123","author":"Vargo","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0030","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/10428190600565651","article-title":"Treatment outcome of front-line systemic chemotherapy for localized extranodal NK\/T cell lymphoma in nasal and upper aerodigestive tract","volume":"47","author":"Kim","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0031","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijrobp.2016.09.013","article-title":"Patterns of primary tumor invasion and regional lymph node spread based on magnetic resonance imaging in early-stage nasal NK\/T-cell lymphoma: Implications for clinical target volume definition and prognostic significance","volume":"97","author":"Wu","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0032","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12032-014-0320-1","article-title":"Prophylactic cervical lymph node irradiation provides no benefit for patients of stage IE extranodal natural killer\/T cell lymphoma, nasal type","volume":"32","author":"Wang","year":"2015","journal-title":"Med Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0033","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: An overview of International Lymphoma Radiation Oncology Group guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0034","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamaoncol.2016.5094","article-title":"Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer\/T-cell lymphoma","volume":"3","author":"Yang","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40880-016-0096-0","article-title":"Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer\/T cell lymphoma","volume":"35","author":"Niu","year":"2016","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0036","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0959-8049(01)00127-7","article-title":"Interpreting quality of life data: Population-based reference data for the EORTC QLQ-C30","volume":"37","author":"Fayers","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0037","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1748-717X-8-152","article-title":"Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer\/T-cell lymphoma nasal type: Dosimetric and clinical results","volume":"8","author":"Shen","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0038","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/ejh.13004","article-title":"Efficacy and tolerance of GELOXD\/P-GEMOXD in newly diagnosed nasal-type extranodal NK\/T-cell lymphoma: A multicenter retrospective study","volume":"100","author":"Li","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0039","first-page":"1420","article-title":"[Analysis of clinical efficacy and influencing factors of gemcitabine-L-asparaginase-oxaliplatin chemotherapy scheme and radiotherapy for treatment of early ENKTL patients]","volume":"25","author":"Qiu","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0040","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3892\/ol.2015.3327","article-title":"First-line combination of GELOX followed by radiation therapy for patients with stage IE\/IIE ENKTL: An updated analysis with long-term follow-up","volume":"10","author":"Wang","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0041","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11899-018-0430-5","article-title":"NK\/T cell lymphoma: Updates in therapy","volume":"13","author":"Suzuki","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0042","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/annonc\/mdx316","article-title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: Clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease","volume":"28","author":"Lim","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0043","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/14737140.2017.1344100","article-title":"L-Asparaginase for newly diagnosed extra-nodal NK\/T-cell lymphoma: Systematic review and meta-analysis","volume":"17","author":"Pokrovsky","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ijrobp.2023.09.031_bib0044","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.2147\/OTT.S116591","article-title":"Radiation dose reduction for patients with extranodal NK\/T-cell lymphoma with complete response after initial induction chemotherapy","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623079440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623079440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:11:22Z","timestamp":1759745482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623079440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0360301623079440"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.09.031","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Clinical Trial of Simultaneous Boost Intensity Modulated Radiation Therapy With 3 Dose Gradients in Patients With Stage I-II Nasal Type Natural Killer\/T-Cell Lymphoma: Long-Term Outcomes of Survival and Quality of Life","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}